Attitudes toward opioid use disorder pharmacotherapy among recovery community center attendees

被引:11
|
作者
Hoffman, Lauren A.
Vilsaint, Corrie L.
Kelly, John F.
机构
[1] Massachusetts Gen Hosp, Recovery Res Inst, 151 Merrimac St, Boston, MA 02114 USA
[2] Harvard Med Sch, 151 Merrimac St, Boston, MA 02114 USA
关键词
Recovery community centers; Opioid use disorder; Buprenorphine; Methadone; Naltrexone; Addiction recovery; SUBSTANCE-ABUSE TREATMENT; ADDICTION TREATMENT; UNITED-STATES; SPIRITUALITY; MEDICATIONS; DRUG; VALIDATION; MEDICINE; ALCOHOL; SUPPORT;
D O I
10.1016/j.jsat.2021.108464
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: Despite their proven efficacy, medications for opioid use disorder (MOUD) are underutilized. Negative beliefs and attitudes toward MOUD are quite common, yet rapidly expanding recovery community centers (RCCs) may offer a promising venue for fostering MOUD support as they operate under the maxim, "many pathways [to recovery], all should be celebrated" and are utilized mainly by those with opioid use disorder. The current study provides a first look at MOUD attitudes and their correlates in RCC attendees. Methods: The study conducted a cross-sectional survey (N = 320) of recovering adults attending 31 RCCs across New England, assessing demographic, treatment, and recovery-relevant factors, as well attitudes (positive vs. negative) toward the use of agonist and antagonist MOUD. The study used frequencies and confidence intervals to obtain prevalence estimates for positive and negative attitudes toward agonist and antagonist MOUD, and to examine differences between them. Spearman correlations identified correlates of MOUD attitudes (at p < 0.10), and significant correlates were assessed for unique contributions via multivariable logistic regression. Results: Positive attitudes were common and more prevalent than negative attitudes for both agonist (positive: 71.4 [66.1, 76.3]%; negative: 28.6 [23.7, 33.9]%) and antagonist (positive: 76.5 [71.4, 81.1]%; negative: 23.5 [18.9, 28.6]%) MOUD, which did not differ. The study identified several correlates of MOUD attitudes at the p < 0.10 level, but only four variables emerged as unique predictors controlling for other correlates. Lifetime history of agonist MOUD treatment was uniquely associated with positive agonist attitudes (p = 0.008), whereas greater social support for recovery was associated with positive antagonist attitudes (p = 0.007). Lower educational attainment was uniquely associated with negative antagonist attitudes (p = 0.005), and a greater degree of spirituality was related to negative attitudes toward both agonists (p = 0.005) and antagonists (p = 0.01). Conclusions: Findings reveal very high rates of positive MOUD attitudes among RCC participants, highlighting the potential for this growing tier of recovery support to foster acceptance and peer support for medication facilitated recovery pathways. Correlates of attitudes further reveal opportunities for facilitating MOUD acceptance within and beyond the RCC network.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Optimizing retention strategies for opioid use disorder pharmacotherapy: The retention phase of the CTN-0100 trial (RDD)
    Shulman, Matisyahu
    Meyers-Ohki, Sarah
    Novo, Patricia
    Provost, Scott
    Ohrtman, Kaitlyn
    Van Veldhuisen, Paul
    Oden, Neal
    Otterstatter, Michael
    Bailey, Genie L.
    Liu, David
    Rotrosen, John
    Weiss, Roger D.
    V. Nunes, Edward
    CONTEMPORARY CLINICAL TRIALS, 2025, 150
  • [32] Medications for Opioid Use Disorder in the Criminal/Legal System: Knowledge, Beliefs, and Attitudes Among Rural Community-Based Stakeholders
    Victor, Grant
    Lee, Guijin
    del Pozo, Brandon
    Silverstein, Sydney
    Zettner, Catherine
    Cason, Rahni
    Ray, Bradley
    JOURNAL OF DRUG ISSUES, 2022, 52 (03) : 389 - 405
  • [33] Associations Between Polysubstance Use Patterns and Receipt of Medications for Opioid Use Disorder Among Adults in Treatment for Opioid Use Disorder
    Ford, Becky R.
    Bart, Gavin
    Grahan, Brian
    Shearer, Riley D.
    Winkelman, Tyler N. A.
    JOURNAL OF ADDICTION MEDICINE, 2021, 15 (02) : 159 - 162
  • [34] Health-related quality of life and recovery capital among recovery residents taking medication for opioid use disorder in Texas
    Obekpa, Elizabeth O.
    McCurdy, Sheryl A.
    Schick, Vanessa
    Markham, Christine M.
    Gallardo, Kathryn R.
    Wilkerson, Johnny Michael
    FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [35] Adverse events among adult Medicaid enrollees with opioid use disorder and substance use disorders
    O'Brien, Peggy
    Henke, Rachel Mosher
    Schaefer, Mary Beth
    Lin, Janice
    Creedon, Timothy B.
    DRUG AND ALCOHOL DEPENDENCE, 2021, 221
  • [36] Effects of Interim Buprenorphine Treatment for opioid use disorder among emerging adults
    Peck, Kelly R.
    Ochalek, Taylor A.
    Badger, Gary J.
    Sigmon, Stacey C.
    DRUG AND ALCOHOL DEPENDENCE, 2020, 208
  • [37] Adherence to and Retention in Medications for Opioid Use Disorder Among Adolescents and Young Adults
    Viera, Adam
    Bromberg, Daniel J.
    Whittaker, Shannon
    Refsland, Bryan M.
    Stanojlovic, Milena
    Nyhan, Kate
    Altice, Frederick L.
    EPIDEMIOLOGIC REVIEWS, 2020, 42 (01) : 41 - 56
  • [38] LINKING OPIOID USE DISORDER TREATMENT FROM HOSPITAL TO COMMUNITY
    Brothers, Thomas D.
    Lewer, Dan
    Thakrar, Ashish P.
    ADDICTION, 2021, 116 (08) : 2244 - 2245
  • [39] Fentanyl exposure and preferences among individuals starting treatment for opioid use disorder
    Gryczynski, Jan
    Nichols, Helen
    Schwartz, Robert P.
    Mitchell, Shannon Gwin
    Hill, Paulette
    Wireman, Kim
    DRUG AND ALCOHOL DEPENDENCE, 2019, 204
  • [40] Evaluation of Resident Physicians' Knowledge of and Attitudes Towards Prescribing Buprenorphine for Patients With Opioid Use Disorder
    Shuey, Bryant
    Lee, Dasom
    Ugalde, Israel
    Borgan, Saif
    Bresnan, Caroline
    Qureshi, Marvi
    Mhaskar, Rahul
    Oxner, Asa
    JOURNAL OF ADDICTION MEDICINE, 2021, 15 (03) : 219 - 225